Sera Prognostics NASDAQ:SERA said that Chief Scientific Officer John J. Boniface executed a sale of 1,517 shares of Class A Common Stock on March 11, 2026, generating approximately $3,094 in proceeds. The disposition took place at a weighted average price of $2.04 per share, with individual transactions in the block ranging from $1.90 to $2.30.
The company disclosed that the share disposition was conducted to satisfy tax withholding obligations tied to the vesting of restricted stock units. After the sale, Boniface is listed as directly holding 145,842 shares of Sera Prognostics.
At the time of the report, Sera Prognostics stock was trading at $1.99. The share price has fallen about 51% over the past year and is down approximately 33% year-to-date.
Summary of market and research context
Market analysis cited in the company disclosure notes that InvestingPro views the stock as appearing undervalued at current levels. InvestingPro commentary additionally points to a relative strength index, or RSI, that suggests the shares are in oversold territory. The reference notes that the RSI insight is one of 10 additional InvestingPro insights available to subscribers, which are provided alongside a comprehensive Pro Research Report on the company’s financial status and outlook.
Sera Prognostics is scheduled to report earnings in five days on March 18.
Clinical readout and analyst action
Separately, the company has announced positive results from a large clinical trial of its PreTRM Test, a blood-based assay intended to identify pregnant women at higher risk for spontaneous preterm birth. The trial enrolled 5,018 women and found that, when the test was paired with targeted interventions, preterm birth rates declined and newborn outcomes improved.
According to the published trial results, the test-and-treat strategy produced a 56% reduction in births before 32 weeks and a 32% reduction in births before 35 weeks. Those results were published in the peer-reviewed journal PREGNANCY.
Jefferies has initiated coverage on Sera Prognostics with a Buy rating and established a price target of $5.00. Company statements also reference the PRIME Study, which demonstrated that women identified as higher risk by the PreTRM blood test experienced better outcomes when provided with specific interventions versus standard prenatal care.
Clear summary
Boniface sold 1,517 shares on March 11, 2026, for approximately $3,094 to meet tax withholding tied to vested RSUs. The company has reported statistically meaningful clinical-trial benefits for the PreTRM Test and has attracted Buy coverage from Jefferies, even as the share price trades near $1.99 following sharp declines over the previous year. Sera Prognostics will report quarterly results on March 18.
Key points
- Insider sale: John J. Boniface sold 1,517 shares on March 11, 2026, at a weighted average price of $2.04 to cover tax withholding from RSU vesting.
- Clinical data: The PreTRM trial of 5,018 women showed a 56% reduction in births before 32 weeks and a 32% reduction before 35 weeks; results published in PREGNANCY.
- Market context: Shares trade at $1.99, down roughly 51% over the last year and 33% year-to-date; Jefferies initiated coverage with a Buy rating and a $5.00 price target.
Risks and uncertainties
- Share-price weakness: The stock has declined about 51% over the past year and is down roughly 33% year-to-date, reflecting market volatility that may affect investor sentiment.
- Near-term event risk: The company is due to report earnings in five days on March 18, creating a potential near-term catalyst and uncertainty for the stock.
- Valuation and sentiment divergence: While InvestingPro describes the stock as appearing undervalued and the RSI as indicating oversold conditions, those technical and analyst views contrast with the recent price decline.